| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H25NO5 |
| Molecular Weight | 335.3948 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CCN3CC=C(COC(=O)[C@](C)(O)[C@H](C)C\C(=C\C)C(=O)O1)[C@]23[H]
InChI
InChIKey=HKODIGSRFALUTA-JTLQZVBZSA-N
InChI=1S/C18H25NO5/c1-4-12-9-11(2)18(3,22)17(21)23-10-13-5-7-19-8-6-14(15(13)19)24-16(12)20/h4-5,11,14-15,22H,6-10H2,1-3H3/b12-4-/t11-,14-,15-,18-/m1/s1
The pyrrolizidine alkaloid senecionine has been shown to produce an increase in cytosolic free Ca2+ concentration in isolated hepatocytes that correlated with an increase in cellular toxicity. Senecionine inhibits the sequestration of Ca2+ in extramitochondrial and mitochondrial compartments possibly by inactivating free sulfhydryl groups and oxidizing pyridine nucleotides respectively. Senecionine showed moderate antitrypanosomal activity with an IC50 value of 41.78 ug/ml.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Pharmacokinetic experiments of intravenous administration
in the jugular-catheterized rat model: An aqueous solution contained senecionine was administered to rats intravenously at dose of 1.5 mg/kg.
Pharmacokinetic experiments of oral administration
in the jugular-catheterized rat model: An
aqueous solution of senecionine was administered orally
to rats by gavage at doses of 24, 12, and 6 mg/kg.
Route of Administration:
Other
SUBSTANCE RECORD
